Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn’s disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811464-colitis-pipeline-review-h1-2018
Top Companies mentioned
Apollo Endosurgery Inc
Bristol-Myers Squibb Co
Concenter BioPharma Silkim Ltd
EA Pharma Co Ltd
Colitis Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Colitis – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Colitis , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 2, 18 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 1 molecules, respectively.
Colitis pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Colitis – Competitive Analysis
Key players are making innovative developments in Colitis industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis.
The pipeline guide reviews pipeline therapeutics for Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Colitis therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Colitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Colitis.
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811464-colitis-pipeline-review-h1-2018
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349